332 related articles for article (PubMed ID: 32576270)
1. Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation.
Gong M; Li Y; Ye X; Zhang L; Wang Z; Xu X; Shen Y; Zheng C
Cell Commun Signal; 2020 Jun; 18(1):98. PubMed ID: 32576270
[TBL] [Abstract][Full Text] [Related]
2. The discovery and characterization of K-563, a novel inhibitor of the Keap1/Nrf2 pathway produced by Streptomyces sp.
Hori R; Yamaguchi K; Sato H; Watanabe M; Tsutsumi K; Iwamoto S; Abe M; Onodera H; Nakamura S; Nakai R
Cancer Med; 2019 Mar; 8(3):1157-1168. PubMed ID: 30735010
[TBL] [Abstract][Full Text] [Related]
3. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
[TBL] [Abstract][Full Text] [Related]
4. ERBB3 and IGF1R Signaling Are Required for Nrf2-Dependent Growth in KEAP1-Mutant Lung Cancer.
Vartanian S; Lee J; Klijn C; Gnad F; Bagniewska M; Schaefer G; Zhang D; Tan J; Watson SA; Liu L; Chen H; Liang Y; Watanabe C; Cuellar T; Kan D; Hartmaier RJ; Lau T; Costa MR; Martin SE; Merchant M; Haley B; Stokoe D
Cancer Res; 2019 Oct; 79(19):4828-4839. PubMed ID: 31416841
[TBL] [Abstract][Full Text] [Related]
5. A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer.
Choi EJ; Jung BJ; Lee SH; Yoo HS; Shin EA; Ko HJ; Chang S; Kim SY; Jeon SM
Oncogene; 2017 Sep; 36(37):5285-5295. PubMed ID: 28504720
[TBL] [Abstract][Full Text] [Related]
6. A Novel Nrf2 Pathway Inhibitor Sensitizes Keap1-Mutant Lung Cancer Cells to Chemotherapy.
Zhang D; Hou Z; Aldrich KE; Lockwood L; Odom AL; Liby KT
Mol Cancer Ther; 2021 Sep; 20(9):1692-1701. PubMed ID: 34158350
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
Torrente L; Prieto-Farigua N; Falzone A; Elkins CM; Boothman DA; Haura EB; DeNicola GM
Redox Biol; 2020 Feb; 30():101440. PubMed ID: 32007910
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer.
Cai MC; Chen M; Ma P; Wu J; Lu H; Zhang S; Liu J; Zhao X; Zhuang G; Yu Z; Fu Y
Int J Cancer; 2019 Feb; 144(4):788-801. PubMed ID: 30411339
[TBL] [Abstract][Full Text] [Related]
9. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
Singh A; Misra V; Thimmulappa RK; Lee H; Ames S; Hoque MO; Herman JG; Baylin SB; Sidransky D; Gabrielson E; Brock MV; Biswal S
PLoS Med; 2006 Oct; 3(10):e420. PubMed ID: 17020408
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
[TBL] [Abstract][Full Text] [Related]
11. Distinct Nrf2 Signaling Thresholds Mediate Lung Tumor Initiation and Progression.
DeBlasi JM; Falzone A; Caldwell S; Prieto-Farigua N; Prigge JR; Schmidt EE; Chio IIC; Karreth FA; DeNicola GM
Cancer Res; 2023 Jun; 83(12):1953-1967. PubMed ID: 37062029
[TBL] [Abstract][Full Text] [Related]
12. Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance.
Jeong Y; Hoang NT; Lovejoy A; Stehr H; Newman AM; Gentles AJ; Kong W; Truong D; Martin S; Chaudhuri A; Heiser D; Zhou L; Say C; Carter JN; Hiniker SM; Loo BW; West RB; Beachy P; Alizadeh AA; Diehn M
Cancer Discov; 2017 Jan; 7(1):86-101. PubMed ID: 27663899
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic KEAP1 mutations activate TRAF2-NFκB signaling to prevent apoptosis in lung cancer cells.
Deen AJ; Adinolfi S; Härkönen J; Patinen T; Liu X; Laitinen T; Takabe P; Kainulainen K; Pasonen-Seppänen S; Gawriyski LM; Arasu UT; Selvarajan I; Mäkinen P; Laitinen H; Kansanen E; Kaikkonen MU; Poso A; Varjosalo M; Levonen AL
Redox Biol; 2024 Feb; 69():103031. PubMed ID: 38184997
[TBL] [Abstract][Full Text] [Related]
14. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth.
Ohta T; Iijima K; Miyamoto M; Nakahara I; Tanaka H; Ohtsuji M; Suzuki T; Kobayashi A; Yokota J; Sakiyama T; Shibata T; Yamamoto M; Hirohashi S
Cancer Res; 2008 Mar; 68(5):1303-9. PubMed ID: 18316592
[TBL] [Abstract][Full Text] [Related]
15. Dihydrotanshinone I inhibits gallbladder cancer growth by targeting the Keap1-Nrf2 signaling pathway and Nrf2 phosphorylation.
Li Z; Mo RL; Gong JF; Han L; Wang WF; Huang DK; Xu JG; Sun YJ; Chen S; Han GC; Sun DQ
Phytomedicine; 2024 Jul; 129():155661. PubMed ID: 38677269
[TBL] [Abstract][Full Text] [Related]
16. Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer.
Tian Y; Wu K; Liu Q; Han N; Zhang L; Chu Q; Chen Y
J Hematol Oncol; 2016 Sep; 9(1):83. PubMed ID: 27601007
[TBL] [Abstract][Full Text] [Related]
17. Microenvironmental Activation of Nrf2 Restricts the Progression of Nrf2-Activated Malignant Tumors.
Hayashi M; Kuga A; Suzuki M; Panda H; Kitamura H; Motohashi H; Yamamoto M
Cancer Res; 2020 Aug; 80(16):3331-3344. PubMed ID: 32636316
[TBL] [Abstract][Full Text] [Related]
18. Proteomic analysis of ubiquitin ligase KEAP1 reveals associated proteins that inhibit NRF2 ubiquitination.
Hast BE; Goldfarb D; Mulvaney KM; Hast MA; Siesser PF; Yan F; Hayes DN; Major MB
Cancer Res; 2013 Apr; 73(7):2199-210. PubMed ID: 23382044
[TBL] [Abstract][Full Text] [Related]
19. p62-Dependent Phase Separation of Patient-Derived KEAP1 Mutations and NRF2.
Cloer EW; Siesser PF; Cousins EM; Goldfarb D; Mowrey DD; Harrison JS; Weir SJ; Dokholyan NV; Major MB
Mol Cell Biol; 2018 Nov; 38(22):. PubMed ID: 30126895
[TBL] [Abstract][Full Text] [Related]
20. [Overexpression of Keap1 inhibits the cell proliferation and metastasis and overcomes the drug resistance in human lung cancer A549 cells].
Weng X; Yan YY; Tong YH; Fan Y; Zeng JM; Wang LL; Lin NM
Zhonghua Zhong Liu Za Zhi; 2016 Jun; 38(6):404-10. PubMed ID: 27346396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]